UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Medulloblastoma
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
This Phase I clinical trial will evaluate the safety and efficacy of MV-NIS, which is administered via injection into the tumor site or subarachnoid space, in treating children and young adults with recurrent medulloblastoma or AT/RT.
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Medulloblastoma
Choroid Plexus Tumors
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
The purpose is to evaluate cognitive, social, emotional, and behavioral functioning over time in patients already enrolled in a Children’s Oncology Group Phase III clinical trial.
Conditions
Craniopharyngioma
This phase II trial will assess the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF-kinase (DAY101) inhibition for the treatment of children and young adults with craniopharyngioma.
Conditions
Glioma
This is a randomized, double-blind, placebo-controlled international phase III study in participants with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy extends overall survival and progression-free survival.
Conditions
Diffuse Midline Glioma
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Pleomorphic xanthoastrocytoma (grades II-III)
Glioblastoma (grade IV)
Brainstem Glioma
Ependymoma
This phase I clinical trial will evaluate ONC206 alone or in combination with radiation therapy in treating pediatric patients with newly diagnosed or recurrent DMGs, or other recurrent primary malignant brain tumors.
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Diffuse astrocytoma (grade II)
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Medulloblastoma
Ependymoma
This phase I clinical trial will study a novel drug called ALRN-6924 for treating children and young adults with recurrent or refractory solid tumors, brain tumors, lymphoma or leukemia.
Conditions
Glioma
Glioblastoma (grade IV)
This is a phase I/II trial that aims to to establish a safe and effective dose of albumin-bound paclitaxel, to demonstrate that the opening of the blood-brain barrier increases chemotherapy concentration in the tumor, and to estimate how effective this treatment is in reducing the tumor burden and prolonging life.
Conditions
Glioma
Astrocytoma
Oligodendroglioma
Ependymoma
The goal of this phase I clinical trial is to demonstrate that a metabolic imaging technology can safely be used in patients with gliomas to help study treatment effects.
Conditions
Medulloblastoma
This phase II clinical trial will evaluate the efficacy of reduced craniospinal radiation therapy in combination with chemotherapy for patients with newly diagnosed WNT-driven medulloblastoma.
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Pleomorphic xanthoastrocytoma (grades II-III)
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Ependymoma
Medulloblastoma
Summary
This phase I/II clinical trial will evaluate REGN2810 (also called cemiplimab) in combination with radiation therapy as a treatment for pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), ne
Conditions
Meningioma
This phase II clinical trial will evaluate the safety and efficacy of stereotactic radiosurgery and pembrolizumab in treating patients with recurrent meningioma (grades I-III).
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Pleomorphic xanthoastrocytoma (grades II-III)
Diffuse astrocytoma (grade II)
This phase I study will evaluate the safety, dose-limiting toxicities, and preliminary efficacy of vorasidenib in combination with pembrolizumab in participants with recurrent or progressive enhancing isocitrate dehydrogenase-1 (IDH-1) mutant astrocytomas.